Immune network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome with atypical and classical presentations

Translational Psychiatry

Volumn 7, Issue 4, 2017, Pages

  Hornig, M ^a   Gottschalk, C G ^b   Eddy, M L ^a   Che, X ^a   Ukaigwe, J E ^a   Peterson, D L ^b   Lipkin, W I ^a,c  

^a Columbia University Mailman School of Public Health ^*  (United States)

^b Sierra Internal Medicine Associates   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CARBON TETRACHLORIDE; CD40 LIGAND; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 7; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NERVE GROWTH FACTOR BETA SUBUNIT; PROTEIN; PROTEIN CSF3; PROTEIN PDGFBB; RANTES; RESISTIN; SERPIN E1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CYTOKINE; IL17A PROTEIN, HUMAN;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CHRONIC FATIGUE SYNDROME; DISEASE DURATION; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN CEREBROSPINAL FLUID LEVEL; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY;

ADULT; CEREBROSPINAL FLUID; CHEMOKINE CXCL9; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED;

EID: 85017003680     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2017.44     Document Type: Article

References (24)

1. Jason LA, Zinn ML, Zinn MA. Myalgic encephalomyelitis: symptoms and biomarkers. Curr Neuropharmacol 2015; 13: 701-734.
2. Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, Tazawa S et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: An (1)(1)C-(R)-PK11195 PET Study. J Nucl Med 2014; 55: 945-950.
3. Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN et al. Distinct cerebrospinal fluid proteomes differentiate post-Treatment lyme disease from chronic fatigue syndrome. PLoS ONE 2011; 6: e17287.
4. Baraniuk JN, Casado B, Maibach H, Clauw DJ, Pannell LK, Hess SS. A chronic fatigue syndrome-related proteome in human cerebrospinal fluid. BMC Neurol 2005; 5: 22.
5. Hornig M, Gottschalk G, Peterson DL, Knox KK, Schultz AF, Eddy ML et al. Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome. Mol Psychiatry 2016; 21: 261-269.
6. Chang CM, Warren JL, Engels EA. Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer 2012; 118: 5929-5936.
7. Calabrese LH, Davis ME, Wilke WS. Chronic fatigue syndrome and a disorder resembling Sjogren's syndrome: preliminary report. Clin Infect Dis 1994; 18: S28-S31.
8. Gaber TA, Oo WW, Ringrose H. Multiple sclerosis/chronic fatigue syndrome overlap: when two common disorders collide. NeuroRehabilitation 2014; 35: 529-534.
9. Daugherty SA, Henry BE, Peterson DL, Swarts RL, Bastien S, Thomas RS. Chronic fatigue syndrome in northern Nevada. Rev Infect Dis 1991; 13: S39-S44.
10. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-959.
11. Carruthers BM, Jain AK, DeMeirleir KL, Peterson DL, Klimas NG, Lerner AM et al. Myalgic Encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatments protocols. J Chronic Fatigue Syndr 2003; 11: 7-115.
12. Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv 2015; 1: e1400121.
13. Martins TB. Development of internal controls for the Luminex instrument as part of a multiplex seven-Analyte viral respiratory antibody profile. Clin Diagn Lab Immunol 2002; 9: 41-45.
14. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000; 243: 243-255.
15. Box GEP, Cox DR. An analysis of transformations. J R Stat Soc Series B 1964; 26: 211-252.
16. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
17. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Series B 1996; 58: 267-288.
18. Breiman L. Random forests. Mach Learn 2001; 45: 5-32.
19. Strobl C, Boulesteix AL, Zeileis A, Hothorn T. Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinformatics 2007; 8: 25.
20. NodeXL: A Free and Open Network Overview, Discovery and Exploration Add-in for Excel 2007/2010. Available at http://nodexl.codeplex.com/(accessed 2010).
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
22. Kostic M, Dzopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stojanovic I et al. IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol 2014; 79: 181-186.
23. Prajeeth CK, Lohr K, Floess S, Zimmermann J, Ulrich R, Gudi V et al. Effector molecules released by Th1 but not Th17 cells drive an M1 response in microglia. Brain Behav Immun 2014; 37: 248-259.
24. Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 2010; 16: 208-217.